+++
title = "Lantern Pharma Reports Complete Metabolic Response in Aggressive Lymphoma Patient Treated with AI-Discovered Drug LP-284"
date = "2025-10-28T15:45:23Z"
draft = false
summary = "Lantern Pharma's AI-driven drug LP-284 achieved a complete metabolic response in a treatment-resistant lymphoma patient, validating the company's artificial intelligence platform for oncology drug discovery and development."
description = "Lantern Pharma's AI-developed cancer drug LP-284 shows complete response in treatment-resistant lymphoma patient. Breakthrough results validate RADRÂ® platform's potential to transform oncology drug discovery."
source_link = "https://rss.investorbrandnetwork.com/ainw/ainewsbreaks-lantern-pharma-nasdaq-ltrn-reports-complete-metabolic-response-in-phase-1-lp-284-trial-at-llm-congress/"
enclosure = "https://cdn.newsramp.app/banners/health-wellness-1.jpg"
article_id = 267603
feed_item_id = 23108
qrcode = "https://cdn.newsramp.app/ibn/qrcode/2510/28/fileATH8.webp"
source = "InvestorBrandNetwork (IBN)"
+++

<p>Lantern Pharma has reported a confirmed complete metabolic response in a patient with aggressive lymphoma treated with its investigational drug LP-284, representing a significant validation of the company's artificial intelligence-driven oncology platform. The 41-year-old patient with Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma achieved this response after failing four prior treatment regimens, including CAR-T and bispecific antibody therapies.</p><p>The response occurred after just two 28-day cycles of LP-284 treatment in the ongoing Phase 1 trial, with data presented at the 25th Annual Lymphoma, Leukemia & Myeloma Congress in New York City. This outcome supports the drug's synthetic lethal mechanism and suggests potential for addressing a critical treatment gap for patients who have exhausted immunotherapy options. The company's RADR AI platform, which leverages over 200 billion oncology-focused data points and more than 200 machine learning algorithms, was instrumental in discovering and developing LP-284.</p><p>Lantern CEO Panna Sharma stated that the results validate the company's AI-driven approach and highlight LP-284's dual potential as both a monotherapy and in combination with FDA-approved agents such as rituximab. The company noted LP-284's favorable early safety profile, multiple FDA Orphan Drug Designations, and strong intellectual property protection through 2039. Additional information about the company's developments is available at <a href="https://ibn.fm/LTRN" rel="nofollow" target="_blank">https://ibn.fm/LTRN</a>.</p><p>This achievement represents a significant validation of artificial intelligence in drug discovery, particularly in oncology where treatment resistance remains a major challenge. Lantern's growing pipeline of therapies spans multiple cancer indications including both solid tumors and blood cancers, with an estimated combined annual market potential exceeding $15 billion. The company's antibody-drug conjugate program and multiple clinical trials, including a Phase 2 program, demonstrate the broad application of their AI platform in accelerating oncology drug development.</p><p>The implications for the pharmaceutical industry are substantial, as AI-driven drug discovery platforms like Lantern's RADR could significantly reduce development timelines and costs while improving success rates. For patients with treatment-resistant cancers, particularly those who have exhausted immunotherapy options, this breakthrough offers new hope for effective therapies. The successful application of AI in identifying and developing LP-284 suggests that similar approaches could be applied to other challenging cancer types, potentially transforming oncology drug development and expanding treatment options for difficult-to-treat malignancies.</p>